Form 4 for TRAW Traws Pharma, Inc.
Accepted 2025-02-19 00:00:00 ET · period of report 2025-02-18 · accession 0001415889-25-004727 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-02-19 | 2025-02-18 | TRAW | CAUTREELS WERNER | CEO, Dir | M - OptEx | $0.01 | +96.3K | 104.3K | +1,204% | +$963.48 |
| D | 2025-02-19 | 2025-02-18 | TRAW | CAUTREELS WERNER | CEO, Dir | M - OptEx | $0.00 | -96.3K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-02-18 | M | A | 96,348 | $0.01 | 104,348 | D | — | — | (F1) The Common Stock was acquired by way of an exercise of Pre-Funded Warrants at an exercise price of $0.01 per Pre-Funded Warrant. The Pre-Funded warrants were acquired as part of Class B Units, with each Class B unit consisting of one Pre-Funded Warrant and one Series A Warrant, at a purchase price of $5.093 per Class B Unit. |
| 2 | Derivative | Pre-Funded Warrant (right to buy) | 2025-02-18 | M | D | 96,348 | $0.00 | 0 | D | $0.01 · — to — | 96,348 Common Stock | (F2) The Pre-Funded Warrants became exercisable upon stockholder approval on February 17, 2025. (F3) The Pre-Funded Warrants do not expire. |